BEACON: A randomised, phase 3 study of encorafenib and cetuximab +/- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients Meeting Abstract
| Authors: | Wasan, H.; Arkenau, T.; Braun, M.; Samuel, L.; Graham, J.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Yoshino, T.; Desai, J.; Ciardello, F.; Gollerkeri, A.; Maharry, K.; Sandor, V.; Christy-Bittel, J.; Anderson, L.; Tabernero, J. |
| Abstract Title: | BEACON: A randomised, phase 3 study of encorafenib and cetuximab +/- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients |
| Meeting Title: | 2019 Cancer Conference of the National Cancer Research Institute (NCRI) |
| Journal Title: | British Journal of Cancer |
| Volume: | 121 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Nov 3-5 |
| Meeting Location: | Glasgow, Scotland |
| ISSN: | 0007-0920 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2019-10-01 |
| Start Page: | 24 |
| Language: | English |
| ACCESSION: | WOS:000505173600067 |
| PROVIDER: | wos |
| PMCID: | PMC6891220 |
| PUBMED: | 31591445 |
| DOI: | 10.1038/s41416-019-0555-x |
| Notes: | Meeting Abstract: 67 -- Source: Wos |
